Time dependent pharmacokinetics of pembrolizumab in patients with solid tumor and its correlation with best overall response

Safety and antitumor activity of biweekly MDX-1106 (Anti-PD-1, BMS-936558/ONO-4538) in patients with advanced refractory malignancies.

(2017) M. Sznol et al.   JOURNAL OF CLINICAL ONCOLOGY

Systematic evaluation of pembrolizumab dosing in patients with advanced non-small-cell lung cancer

(2016) M. Chatterjee et al.   ANNALS OF ONCOLOGY

Programmed Death-1 Blockade With Pembrolizumab in Patients With Classical Hodgkin Lymphoma After Brentuximab Vedotin Failure

(2016) Philippe Armand et al.   JOURNAL OF CLINICAL ONCOLOGY

Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial

(2016) Roy S Herbst et al.   LANCET

Pembrolizumab for classical Hodgkin's lymphoma

(2016) Talha Khan Burki   LANCET ONCOLOGY

Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial

(2016) Tanguy Y Seiwert et al.   LANCET ONCOLOGY

A pharmacokinetic binding model for bevacizumab and VEGF165 in colorectal cancer patients

(2015) Eirini Panoilia et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Quantitative pharmacology of denosumab in patients with bone metastases from solid tumors

(2015) Juan Jose Perez Ruixo et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial

(2015) Antoni Ribas et al.   LANCET ONCOLOGY

Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer

(2015) Edward B. Garon et al.   NEW ENGLAND JOURNAL OF MEDICINE

Pembrolizumab versus Ipilimumab in Advanced Melanoma

(2015) Caroline Robert et al.   NEW ENGLAND JOURNAL OF MEDICINE

Cancer and systemic inflammation: treat the tumour and treat the host

(2014) C S D Roxburgh et al.   BRITISH JOURNAL OF CANCER

Population pharmacokinetic analysis of free and bound aflibercept in patients with advanced solid tumors

(2013) Hoai-Thu Thai et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

The Combination of Exposure-Response and Case-Control Analyses in Regulatory Decision Making

(2012) Jun Yang et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Prediction-Corrected Visual Predictive Checks for Diagnosing Nonlinear Mixed-Effects Models

(2011) Martin Bergstrand et al.   AAPS Journal

The PD-1 pathway in tolerance and autoimmunity

(2010) Loise M. Francisco et al.   IMMUNOLOGICAL REVIEWS

Immune Regulation of Cancer

(2010) Mary L. Disis   JOURNAL OF CLINICAL ONCOLOGY

High expression of PD-L1 in lung cancer may contribute to poor prognosis and tumor cells immune escape through suppressing tumor infiltrating dendritic cells maturation

(2010) Chuan-Yong Mu et al.   MEDICAL ONCOLOGY

Overexpression of PD-L1 Significantly Associates with Tumor Aggressiveness and Postoperative Recurrence in Human Hepatocellular Carcinoma

(2009) Q. Gao et al.   CLINICAL CANCER RESEARCH

PD-1 Is a Regulator of NY-ESO-1-Specific CD8+ T Cell Expansion in Melanoma Patients

(2009) J. Fourcade et al.   JOURNAL OF IMMUNOLOGY

Melanoma Arising in African-, Asian-, Latino- and Native-American Populations

(2009) Brenda A. Shoo et al.   SEMINARS IN CUTANEOUS MEDICINE AND SURGERY